“Summary
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) is a pharmaceutical company. It identifies, develops, manufactures, procures and commercializes ethical drugs and over the counter (OTC) pharmaceutical products. The company develops its ethical drugs for autoimmune disease, diabetes and kidney disease, central nervous system (CNS) disease, other disease and vaccine. It supplies its pharmaceuticals products to pharmaceutical wholesalers, and then to hospitals, clinics, and drugstores, and then to patients. It also undertakes business operations related to fine chemicals, information services, real-estate leasing and advertising, among others. The company caters to Asia, Europe, North America and others. The company is a subsidiary of Mitsubishi Chemical Holdings Corporation. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.
Mitsubishi Tanabe Pharma Corporation – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company鈥檚 (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
– The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
– The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
– Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company鈥檚 operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
– Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
– Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.”
“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 7
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 8
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 9
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 10
Mitsubishi Tanabe Pharma Corporation, Medical Devices Deals, 2009 to YTD 2015 12
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 13
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deal Details 19
Partnerships 19
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 19
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 20
AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 21
Medicago Enters Into Co-Development Agreement With A Global Pharma Company 23
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 24
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 25
Mitsubishi Tanabe Pharma Enters Into Co-Marketing Agreement With Daiichi Sankyo For MP-513 And TA-7284 27
Medicago Enters Into Co-Development Agreement With Cellectis 28
X-BODY Enters Into Research Agreement With Tanabe Research Labs 29
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 30
Medicago Enters Into Research Collaboration With USAMRIID 31
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 32
Mitsubishi Tanabe Pharma Terminates Its Co-Development Agreement With Nycomed International 33
Tanabe Research Labs Enters Into Co-Development Agreement With Anaphore 34
PeptiDream Enters into Drug Discovery Agreement with Mitsubishi Tanabe Pharma 35
Medicago Extends Agreement With Genopole 36
Medicago Enters Into Research Collaboration With PATH 37
GlaxoSmithKline Terminates Co-Promotion Agreement With Mitsubishi Tanabe 38
Medicago Enters Into Memorandum Of Understanding With PT. Bio Farma 39
Medicago Enters Into Memorandum Of Understanding With NITT Partners 40
Mochida Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma 41
Medicago Signs Agreement With Tabuk Pharma 42
Medicago Enters Into Co-Development Agreement With Ajanta Pharma 43
Medicago Enters Into Joint Venture Agreement With Genopole 44
Medicago Enters Into Research Collaboration With SNC-Lavalin, Laval University And McGill University 45
deCODE biostructures Expands Research Agreement With Mitsubishi Tanabe Pharma 47
Affectis Pharma Enters Into Drug Discovery Collaboration With Mitsubishi Tanabe 48
GlaxoSmithKline Enters Into Co-Promotion Agreement with Mitsubishi Tanabe Pharma 49
Merger 50
Bensis To Merge With Japanese Red Cross Plasma Fractionation Center 50
Licensing Agreements 51
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 51
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 53
BioInvent Extends Licensing Agreement With Mitsubishi Tanabe Pharma For Therapeutic Antibodies 55
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 57
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 59
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 60
Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 62
Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 63
OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 64
Cytochroma Terminates Licensing Agreement With Mitsubishi Tanabe Pharma For Lunacalcipol 65
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 67
Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820 69
Handok Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe pharma 70
Dong-A Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For TALION 71
Mitsubishi Tanabe Pharma Terminates Its Licensing Agreement With R-Tech Ueno 72
Daiichi Sankyo Enters Into Sub-Licensing Agreement With Mitsubishi Tanabe Pharma 73
Kureha Enters Into Licensing Agreement With Mitsubishi Tanabe 74
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia 75
BioInvent Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma 77
Vertex Pharma Amends Agreement With Mitsubishi Tanabe Pharma 78
Mitsubishi Tanabe Enters Into Licensing Agreement With EnVivo Pharma 80
Equity Offering 81
Medicago Announces Private Placement Of Common Stock For US$3.4 Million 81
Medicago Completes Second Tranche Of Private Placement Of Shares For US$11 Million 82
Medicago Completes Private Placement Of Common Stock For US$24.5 Million 84
Medicago Completes Public Offering Of Units For US$17.72 Million 86
Medicago Completes Private Placement Of Units For US$7.3 Million 88
Medicago Enters Into Standby Equity Distribution Agreement For US$10 Million 90
Medicago Completes Private Placement Of US$11 Million 91
Asset Transactions 93
Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 93
Acquisition 94
CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 94
Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 95
Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 97
Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 101
Mitsubishi Tanabe Pharma Corporation – Key Competitors 102
Key Employees 103
Locations And Subsidiaries 104
Head Office 104
Other Locations & Subsidiaries 104
Appendix 108
Methodology 108
About GlobalData 108
Contact Us 108
Disclaimer 108″
“List of Tables
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Key Facts, 2014 1
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 7
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 8
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 9
Mitsubishi Tanabe Pharma Corporation, Deals By Therapy Area, 2009 to YTD 2015 10
Mitsubishi Tanabe Pharma Corporation, Medical Devices Deals, 2009 to YTD 2015 12
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 13
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 19
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 20
AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 21
Medicago Enters Into Co-Development Agreement With A Global Pharma Company 23
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 24
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 25
Mitsubishi Tanabe Pharma Enters Into Co-Marketing Agreement With Daiichi Sankyo For MP-513 And TA-7284 27
Medicago Enters Into Co-Development Agreement With Cellectis 28
X-BODY Enters Into Research Agreement With Tanabe Research Labs 29
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 30
Medicago Enters Into Research Collaboration With USAMRIID 31
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 32
Mitsubishi Tanabe Pharma Terminates Its Co-Development Agreement With Nycomed International 33
Tanabe Research Labs Enters Into Co-Development Agreement With Anaphore 34
PeptiDream Enters into Drug Discovery Agreement with Mitsubishi Tanabe Pharma 35
Medicago Extends Agreement With Genopole 36
Medicago Enters Into Research Collaboration With PATH 37
GlaxoSmithKline Terminates Co-Promotion Agreement With Mitsubishi Tanabe 38
Medicago Enters Into Memorandum Of Understanding With PT. Bio Farma 39
Medicago Enters Into Memorandum Of Understanding With NITT Partners 40
Mochida Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma 41
Medicago Signs Agreement With Tabuk Pharma 42
Medicago Enters Into Co-Development Agreement With Ajanta Pharma 43
Medicago Enters Into Joint Venture Agreement With Genopole 44
Medicago Enters Into Research Collaboration With SNC-Lavalin, Laval University And McGill University 45
deCODE biostructures Expands Research Agreement With Mitsubishi Tanabe Pharma 47
Affectis Pharma Enters Into Drug Discovery Collaboration With Mitsubishi Tanabe 48
GlaxoSmithKline Enters Into Co-Promotion Agreement with Mitsubishi Tanabe Pharma 49
Bensis To Merge With Japanese Red Cross Plasma Fractionation Center 50
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 51
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 53
BioInvent Extends Licensing Agreement With Mitsubishi Tanabe Pharma For Therapeutic Antibodies 55
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 57
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 59
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 60
Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 62
Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 63
OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 64
Cytochroma Terminates Licensing Agreement With Mitsubishi Tanabe Pharma For Lunacalcipol 65
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 67
Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820 69
Handok Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe pharma 70
Dong-A Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For TALION 71
Mitsubishi Tanabe Pharma Terminates Its Licensing Agreement With R-Tech Ueno 72
Daiichi Sankyo Enters Into Sub-Licensing Agreement With Mitsubishi Tanabe Pharma 73
Kureha Enters Into Licensing Agreement With Mitsubishi Tanabe 74
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia 75
BioInvent Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma 77
Vertex Pharma Amends Agreement With Mitsubishi Tanabe Pharma 78
Mitsubishi Tanabe Enters Into Licensing Agreement With EnVivo Pharma 80
Medicago Announces Private Placement Of Common Stock For US$3.4 Million 81
Medicago Completes Second Tranche Of Private Placement Of Shares For US$11 Million 82
Medicago Completes Private Placement Of Common Stock For US$24.5 Million 84
Medicago Completes Public Offering Of Units For US$17.72 Million 86
Medicago Completes Private Placement Of Units For US$7.3 Million 88
Medicago Enters Into Standby Equity Distribution Agreement For US$10 Million 90
Medicago Completes Private Placement Of US$11 Million 91
Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 93
CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 94
Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 95
Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 97
Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 101
Mitsubishi Tanabe Pharma Corporation, Key Competitors 102
Mitsubishi Tanabe Pharma Corporation, Key Employees 103
Mitsubishi Tanabe Pharma Corporation, Other Locations 104
Mitsubishi Tanabe Pharma Corporation, Subsidiaries 105″
“List of Figures
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 7
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 8
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 9
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 10
Mitsubishi Tanabe Pharma Corporation, Medical Devices Deals, 2009 to YTD 2015 12″
